Skip to main content
SpringerLink
Log in

Tricuspid Regurgitation: When and How to Treat

  • Valvular Heart Disease (J Dal-Bianco, Section Editor)
  • Published:
Current Treatment Options in Cardiovascular Medicine Aims and scope Submit manuscript

Abstract

Purpose of review

Clinically significant tricuspid regurgitation (TR) is increasingly prevalent in the aging population. TR is a progressive disease associated with worse outcomes, and therefore should be treated appropriately and in a timely manner. This review will summarize the indications for treatment of TR, and the invasive modalities currently available or under development for the management of TR.

Recent findings

Despite its association with increased morbidity and mortality, surgery for isolated TR is uncommon due to increased operative risk. Various transcatheter tricuspid valve (TV) therapies have been developed as an alternative to surgery to address this unmet clinical need. Transcatheter TV repair devices improve leaflet coaptation either directly by bringing the leaflets together (coaptation devices) or indirectly by repairing the dilated tricuspid annulus (annuloplasty devices), whereas orthotopic transcatheter TV replacement involves implantation of a prosthesis in the tricuspid position. Recent first-in-man and phase 1/2 clinical investigations have demonstrated high procedural success rates with reasonable safety and efficacy.

Summary

Transcatheter TV therapies may offer a less invasive and potentially safer alternative to surgery for the management of severe symptomatic TR. Ongoing studies will shed light on long-term outcomes and device durability, and inform patient selection and optimal timing of intervention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References and Recommended Reading

Papers of particular interest, published recently, have been highlighted as • Of importance •• Of major importance

  1. Kolte D, Elmariah S. Transcatheter tricuspid valve therapy. Curr Treat Options Cardiovasc Med. 2019;21(6):26. https://doi.org/10.1007/s11936-019-0730-7.

    Article  PubMed  Google Scholar 

  2. Asmarats L, Puri R, Latib A, Navia JL, Rodés-Cabau J. Transcatheter tricuspid valve interventions. J Am Coll Cardiol. 2018;71(25):2935–56. https://doi.org/10.1016/j.jacc.2018.04.031.

    Article  PubMed  Google Scholar 

  3. Guillaume L, Jean-Philippe C. The tricuspid valve. JACC Cardiovasc Interv. 2019;12(24):2496–8. https://doi.org/10.1016/j.jcin.2019.10.052.

    Article  Google Scholar 

  4. Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of tricuspid regurgitation in patients diagnosed in the community setting. JACC Cardiovasc Imaging. 2019;12(3):433–42. https://doi.org/10.1016/j.jcmg.2018.06.014.

    Article  PubMed  Google Scholar 

  5. Cahill TJ, Prothero A, Wilson J, et al. Community prevalence, mechanisms and outcome of mitral or tricuspid regurgitation. Heart. Published online March 4, 2021. doi:https://doi.org/10.1136/heartjnl-2020-318,482

  6. Arsalan M, Walther T, Smith RL, Grayburn PA. Tricuspid regurgitation diagnosis and treatment. Eur Heart J. 2017;38(9):634–8. https://doi.org/10.1093/eurheartj/ehv487.

    Article  PubMed  Google Scholar 

  7. Muntané-Carol G, Alperi A, Faroux L, et al. Transcatheter interventions for tricuspid valve disease: what to do and who to do it on. Can J Cardiol. Published online January 22, 2021. doi:https://doi.org/10.1016/j.cjca.2020.12.029

  8. Taramasso M, Gavazzoni M, Maisano F. Is tricuspid regurgitation a prognostic interventional target or is it just an indicator of worst prognosis in heart failure patients? Eur Heart J. 2019;40(5):485–7. https://doi.org/10.1093/eurheartj/ehy722.

    Article  PubMed  Google Scholar 

  9. Koelling TM, Aaronson KD, Cody RJ, Bach DS, Armstrong WF. Prognostic significance of mitral regurgitation and tricuspid regurgitation in patients with left ventricular systolic dysfunction. Am Heart J. 2002;144(3):524–9. https://doi.org/10.1067/mhj.2002.123575.

    Article  PubMed  Google Scholar 

  10. • Wang N, Fulcher J, Abeysuriya N, et al. Tricuspid regurgitation is associated with increased mortality independent of pulmonary pressures and right heart failure: a systematic review and meta-analysis. Eur Heart J. 2019;40(5):476–84. https://doi.org/10.1093/eurheartj/ehy641 This study established tricuspid regurgitation as an independent prognostic marker of increased mortality.

    Article  CAS  PubMed  Google Scholar 

  11. Nath J, Foster E, Heidenreich PA. Impact of tricuspid regurgitation on long-term survival. J Am Coll Cardiol. 2004;43(3):405–9. https://doi.org/10.1016/j.jacc.2003.09.036.

    Article  PubMed  Google Scholar 

  12. Benfari G, Antoine C, Miller WL, et al. Excess mortality associated with functional tricuspid regurgitation complicating heart failure with reduced ejection fraction. Circulation. 2019;140(3):196–206. https://doi.org/10.1161/CIRCULATIONAHA.118.038946.

    Article  CAS  PubMed  Google Scholar 

  13. Essayagh B, Antoine C, Benfari G, et al. Functional tricuspid regurgitation of degenerative mitral valve disease: a crucial determinant of survival. Eur Heart J. 2020;41(20):1918–29. https://doi.org/10.1093/eurheartj/ehaa192.

    Article  PubMed  Google Scholar 

  14. Writing Committee Members, Otto CM, Nishimura RA, et al. 2020 ACC/AHA guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2021;77(4):450–500. https://doi.org/10.1016/j.jacc.2020.11.035 Most recent American College of Cardiology/American Heart Association Clinical Practice Guidelines for the management of valvular heart disease.

  15. Kim Y-J, Kwon D-A, Kim H-K, et al. Determinants of surgical outcome in patients with isolated tricuspid regurgitation. Circulation. 2009;120(17):1672–8. https://doi.org/10.1161/CIRCULATIONAHA.109.849448.

    Article  PubMed  Google Scholar 

  16. Topilsky Y, Khanna AD, Oh JK, et al. Preoperative factors associated with adverse outcome after tricuspid valve replacement. Circulation. 2011;123(18):1929–39. https://doi.org/10.1161/CIRCULATIONAHA.110.991018.

    Article  PubMed  Google Scholar 

  17. Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91. https://doi.org/10.1093/eurheartj/ehx391 Most recent European clinical practice guidelines for the management of valvular heart disease.

  18. Hinojar Baydes R, De Angelis V, Garcia-Martin A, et al. Prognostic value of right ventricular systolic function by speckle tracking echocardiography beyond conventional echocardiography in significant tricuspid regurgitation. Eur Heart J 2020;41(Supplement_2). doi:https://doi.org/10.1093/ehjci/ehaa946.1912

  19. Prihadi EA, van der Bijl P, Marlieke D, et al. Prognostic implications of right ventricular free wall longitudinal strain in patients with significant functional tricuspid regurgitation. Circ Cardiovasc Imaging. 2019;12(3):e008666. https://doi.org/10.1161/CIRCIMAGING.118.008666.

    Article  PubMed  Google Scholar 

  20. Ancona F, Melillo F, Calvo F et al. Right ventricular systolic function in severe tricuspid regurgitation: prognostic relevance of longitudinal strain. Eur Heart J - Cardiovasc Imaging. 2021;(jeab030). doi:https://doi.org/10.1093/ehjci/jeab030

  21. Park J-B, Kim H-K, Jung J-H, et al. Prognostic value of cardiac MR imaging for preoperative assessment of patients with severe functional tricuspid regurgitation. Radiology. 2016;280(3):723–34. https://doi.org/10.1148/radiol.2016151556.

    Article  PubMed  Google Scholar 

  22. Kim H-K, Kim Y-J, Park E-A, et al. Assessment of haemodynamic effects of surgical correction for severe functional tricuspid regurgitation: cardiac magnetic resonance imaging study. Eur Heart J. 2010;31(12):1520–8. https://doi.org/10.1093/eurheartj/ehq063.

    Article  PubMed  Google Scholar 

  23. Simone R, Dell'atti D, Judd Robert M., et al. Prognostic value of feature-tracking right ventricular longitudinal strain in severe functional tricuspid regurgitation. JACC Cardiovasc Imaging doi:https://doi.org/10.1016/j.jcmg.2021.02.009

  24. Zack CJ, Fender EA, Chandrashekar P, et al. National trends and outcomes in isolated tricuspid valve surgery. J Am Coll Cardiol. 2017;70(24):2953–60. https://doi.org/10.1016/j.jacc.2017.10.039.

    Article  PubMed  Google Scholar 

  25. Di Mauro M, Lorusso R, Parolari A, et al. The best approach for functional tricuspid regurgitation: a network meta-analysis. J Card Surg. Published online March 2, 2021. doi:https://doi.org/10.1111/jocs.15378

  26. Marquis-Gravel G, Bouchard D, Perrault LP, et al. Retrospective cohort analysis of 926 tricuspid valve surgeries: clinical and hemodynamic outcomes with propensity score analysis. Am Heart J. 2012;163(5):851–8. e1. https://doi.org/10.1016/j.ahj.2012.02.010.

  27. Antunes MJ, Rodríguez-Palomares J, Prendergast B, et al. Management of tricuspid valve regurgitation: position statement of the European Society of Cardiology Working Groups of Cardiovascular Surgery and Valvular Heart Disease. Eur J Cardiothorac Surg. 2017;52(6):1022–30. https://doi.org/10.1093/ejcts/ezx279.

    Article  PubMed  Google Scholar 

  28. Lee J-W, Song J-M, Park JP, Lee JW, Kang D-H, Song J-K. Long-term prognosis of isolated significant tricuspid regurgitation. Circ J Off J Jpn Circ Soc. 2010;74(2):375–80. https://doi.org/10.1253/circj.cj-09-0679.

    Article  Google Scholar 

  29. Axtell AL, Bhambhani V, Moonsamy P, et al. Surgery does not improve survival in patients with isolated severe tricuspid regurgitation. J Am Coll Cardiol. 2019;74(6):715–25. https://doi.org/10.1016/j.jacc.2019.04.028.

    Article  PubMed  Google Scholar 

  30. Dahou A, Levin D, Reisman M, Hahn RT. Anatomy and physiology of the tricuspid valve. JACC Cardiovasc Imaging. 2019;12(3):458–68. https://doi.org/10.1016/j.jcmg.2018.07.032.

    Article  PubMed  Google Scholar 

  31. Hołda MK. Zhingre Sanchez Jorge D., Bateman Michael G., Iaizzo Paul A. Right atrioventricular valve leaflet morphology redefined. JACC Cardiovasc Interv. 2019;12(2):169–78. https://doi.org/10.1016/j.jcin.2018.09.029.

    Article  PubMed  Google Scholar 

  32. Kolte D, Elmariah S. Current state of transcatheter tricuspid valve repair. Cardiovasc Diagn Ther. 2020;10(1):89–97. https://doi.org/10.21037/cdt.2019.09.11.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Williams AM, Bolling SF, Latib A. The five Ws of transcatheter tricuspid valve repair: who, what, when, where, and why. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2019;15(10):841–5. https://doi.org/10.4244/EIJV15I10A159.

    Article  Google Scholar 

  34. Maurizio T, Hannes A, Azeem L, et al. Outcomes after current transcatheter tricuspid valve intervention. JACC Cardiovasc Interv. 2019;12(2):155–65. https://doi.org/10.1016/j.jcin.2018.10.022 This article describes the 30-day and 6-month outcomes of patients enrolled in a large, prospective international registry to evaluate the clinical applications of transcatheter tricuspid valve intervention with different devices.

  35. Michael M, Maurizio T, Christian B, et al. 1-Year Outcomes after edge-to-edge valve repair for symptomatic tricuspid regurgitation. JACC Cardiovasc Interv. 2019;12(15):1451–61. https://doi.org/10.1016/j.jcin.2019.04.019 This multicenter international registry reports 1-year clinical and echocardiographic outcomes of patients treated with tricuspid edge-to-edge repair.

  36. Raghunathan D, Garcia-Sayan E, Schechter M, Napierkowski S, Dhoble A, Smalling R. First-in-human report of MitraClip G4 implantation for torrential tricuspid regurgitation and severe secondary mitral regurgitation. JACC Cardiovasc Interv. 2020;13(13):1599–602. https://doi.org/10.1016/j.jcin.2020.02.034.

    Article  PubMed  Google Scholar 

  37. Daniel B, Mathias O, Martin O, et al. Transcatheter edge-to-edge repair for severe tricuspid regurgitation using the triple-orifice technique versus the bicuspidalization technique. JACC Cardiovasc Interv. 2018;11(17):1790–2. https://doi.org/10.1016/j.jcin.2018.05.049.

    Article  Google Scholar 

  38. Nickenig G, Weber M, Lurz P, et al. Transcatheter edge-to-edge repair for reduction of tricuspid regurgitation: 6-month outcomes of the TRILUMINATE single-arm study. Lancet Lond Engl. 2019;394(10213):2002–11. https://doi.org/10.1016/S0140-6736(19)32600-5 This prospective, multicentre, single-arm study demonstrated the safety and effectiveness of TriClip at 6-months.

  39. Fam Neil P., Braun Daniel, von Bardeleben Ralph Stephan, et al. Compassionate use of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation. JACC Cardiovasc Interv 2019;12(24):2488–2495. Doi:https://doi.org/10.1016/j.jcin.2019.09.046

  40. Kodali S, Hahn RT, Eleid MF, et al. Feasibility study of the transcatheter valve repair system for severe tricuspid regurgitation. J Am Coll Cardiol. 2021;77(4):345–56. https://doi.org/10.1016/j.jacc.2020.11.047 This is the first 30-day report of the single-arm, multicenter, prospective CLASP TR early feasibility study of the PASCAL transcatheter valve repair system.

  41. Holger T, Philipp L. The mistral device for transcatheter tricuspid valve repair. JACC Cardiovasc Interv. 2020;13(18):2097–8. https://doi.org/10.1016/j.jcin.2020.07.040.

    Article  Google Scholar 

  42. David P, Ronen B, Danenberg Haim D. First-in-human transcatheter tricuspid valve repair. JACC Cardiovasc Interv. 2020;13(18):2091–6. https://doi.org/10.1016/j.jcin.2020.05.050.

    Article  Google Scholar 

  43. Mitralix. MATTERS study—mistral percutaneous tricuspid valve repair FIM study. clinicaltrials.gov; 2021. Accessed March 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04071652

  44. Mitralix. MATTERS II—mistral percutaneous tricuspid valve repair FIM study. clinicaltrials.gov; 2021. Accessed March 8, 2021. https://clinicaltrials.gov/ct2/show/NCT04073979

  45. Puri R, Rodés-Cabau J. The FORMA repair system. Interv Cardiol Clin. 2018;7(1):47–55. https://doi.org/10.1016/j.iccl.2017.08.007.

    Article  PubMed  Google Scholar 

  46. Asmarats L, Perlman G, Praz F, et al. Long-term outcomes of the FORMA transcatheter tricuspid valve repair system for the treatment of severe tricuspid regurgitation: insights from the first-in-human experience. JACC Cardiovasc Interv. 2019;12(15):1438–47. https://doi.org/10.1016/j.jcin.2019.04.038 This multicenter study reports the 2-year clinical and echocardiographic outcomes of 18 patients treated with the FORMA system.

  47. Edwards Lifesciences. Early feasibility study of the Edwards FORMA tricuspid transcatheter repair system. clinicaltrials.gov; 2019. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT02471807

  48. Edwards Lifesciences. The SPACER Trial—repair of tricuspid valve regurgitation using the Edwards TricuSPid TrAnsCatheter REpaiR system. clinicaltrials.gov; 2020. Accessed March 8, 2021. https://clinicaltrials.gov/ct2/show/NCT02787408

  49. Messika-Zeitoun D, Nickenig G, Latib A, et al. Transcatheter mitral valve repair for functional mitral regurgitation using the Cardioband system: 1 year outcomes. Eur Heart J. 2019;40(5):466–72. https://doi.org/10.1093/eurheartj/ehy424.

    Article  PubMed  Google Scholar 

  50. Nickenig G, Weber M, Schueler R, et al. 6-Month outcomes of tricuspid valve reconstruction for patients with severe tricuspid regurgitation. J Am Coll Cardiol. 2019;73(15):1905–15. https://doi.org/10.1016/j.jacc.2019.01.062.

    Article  PubMed  Google Scholar 

  51. Edwards Granted CE Mark for first transcatheter tricuspid therapy | Edwards Lifesciences Switzerland. Accessed Mar 10, 2021. https://www.edwards.com/ch-en/news-releases/edwards-granted-ce-mark-for-first-transcatheter-tricuspid-therapy/

  52. Anderson A, Hausleiter J, von Bardeleben RS, et al. One-year outcomes of the TRI-REPAIR study assessing cardioband tricuspid valve reconstruction system for patients with functional tricuspid regurgitation. J Card Fail. 2019;25(8, Supplement):S11. https://doi.org/10.1016/j.cardfail.2019.07.034.

    Article  Google Scholar 

  53. Nickenig G, Weber M, Schüler R, et al. Tricuspid valve repair with the Cardioband system: two-year outcomes of the multicentre, prospective TRI-REPAIR study. EuroIntervention J Eur Collab Work Group Interv Cardiol Eur Soc Cardiol. 2021;16(15):e1264–71. https://doi.org/10.4244/EIJ-D-20-01107 This multicenter prospective study reports the favourable 2-year clinical and echocardiographic outcomes of 30 patients treated with the Cardioband system.

  54. Davidson CJ, Lim D. Scott, Smith Robert L., et al. Early feasibility study of Cardioband tricuspid system for functional tricuspid regurgitation. JACC Cardiovasc Interv. 2021;14(1):41–50. https://doi.org/10.1016/j.jcin.2020.10.017 This multicenter early feasibility study study reports for the first time the 30-day clinical and echocardiographic outcomes of the first United States study with the Cardioband tricuspid valve reconstruction system.

  55. Edwards Lifesciences. Transcatheter repair of tricuspid regurgitation with Cardioband TR System Post-Market Clinical Follow-Up Study (TriBAND): a European prospective, multicenter post-market clinical follow-up study to assess transcatheter tricuspid valve repair with Edwards Cardioband TR System in patients with symptomatic chronic functional tricuspid regurgitation. clinicaltrials.gov; 2021. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT03779490

  56. Schofer J, Bijuklic K, Tiburtius C, Hansen L, Groothuis A, Hahn RT. First-in-human transcatheter tricuspid valve repair in a patient with severely regurgitant tricuspid valve. J Am Coll Cardiol. 2015;65(12):1190–5. https://doi.org/10.1016/j.jacc.2015.01.025.

    Article  PubMed  Google Scholar 

  57. Hahn RT, Meduri CU, Davidson CJ, et al. Early feasibility study of a transcatheter tricuspid valve annuloplasty: SCOUT Trial 30-day results. J Am Coll Cardiol. 2017;69(14):1795–806. https://doi.org/10.1016/j.jacc.2017.01.054 This prospective, single-arm, multicenter, early feasibility study reports the 30-day outcomes of 15 patients treated with the Trialign device.

  58. Mitralign, Inc. Safety and performance of the Trialign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) for symptomatic chronic functional tricuspid regurgitation. clinicaltrials.gov; 2018. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT03225612

  59. Christelle C, Maurizio T, Andrea G, et al. Successful TriCinch-in-TriCinch transcatheter tricuspid valve repair. JACC Cardiovasc Interv. 2017;10(8):e75–7. https://doi.org/10.1016/j.jcin.2017.01.032.

    Article  Google Scholar 

  60. Azeem L, Eustachio A, Alberto P, et al. First-in-man implantation of a tricuspid annular remodeling device for functional tricuspid regurgitation. JACC Cardiovasc Interv. 2015;8(13):e211–4. https://doi.org/10.1016/j.jcin.2015.06.028.

    Article  Google Scholar 

  61. 4Tech Cardio Ltd. Percutaneous treatment of tricuspid valve regurgitation with the TriCinch System™. clinicaltrials.gov; 2018. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT02098200

  62. Giannini F, Colombo A. Percutaneous treatment of tricuspid valve in refractory right heart failure. Eur Heart J Suppl J Eur Soc Cardiol. 2019;21(Suppl B):B43–7. https://doi.org/10.1093/eurheartj/suz031.

    Article  Google Scholar 

  63. 4Tech Cardio Ltd. Clinical trial evaluation of the percutaneous 4Tech TriCinch Coil tricuspid valve repair system. clinicaltrials.gov; 2020. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT03294200

  64. 4Tech Cardio Ltd. Early feasibility study of the percutaneous 4Tech TriCinch Coil tricuspid valve repair system. clinicaltrials.gov; 2020. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT03632967

  65. Cardiac Implants Da Vingi… Proof of concept—technology and clinical updates. TCTMD.com. Accessed Mar 10, 2021. https://www.tctmd.com/slide/cardiac-implants-da-vingi-proof-concept-technology-and-clinical-updates

  66. Cardiac Implants LLC. A first in human study to assess safety and performance of the DaVingi™ System in the treatment of patients with functional tricuspid regurgitation. clinicaltrials.gov; 2021. . https://clinicaltrials.gov/ct2/show/NCT03700918

  67. Rogers T, Ratnayaka K, Sonmez M, et al. Transatrial intrapericardial tricuspid annuloplasty. JACC Cardiovasc Interv. 2015;8(3):483–91. https://doi.org/10.1016/j.jcin.2014.10.013.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Rogers JH, Boyd WD, Smith TW, Bolling SF. Transcatheter mitral valve direct annuloplasty with the Millipede IRIS Ring. Interv Cardiol Clin. 2019;8(3):261–7. https://doi.org/10.1016/j.iccl.2019.02.001.

    Article  PubMed  Google Scholar 

  69. Rogers JH, Boyd WD, Smith TWR, Ebner AA, Grube E, Bolling SF. Transcatheter annuloplasty for mitral regurgitation with an adjustable semi-rigid complete ring: initial experience with the Millipede IRIS Device. Struct Heart. 2018;2(1):43–50. https://doi.org/10.1080/24748706.2017.1385879.

    Article  Google Scholar 

  70. Micro Interventional Devices. Study of transcatheter tricuspid annular repair. clinicaltrials.gov; 2020. Accessed Mar 8, 2021. https://clinicaltrials.gov/ct2/show/NCT03692598

  71. Khan JM, Rogers T, Schenke WH, et al. Transcatheter pledget-assisted suture tricuspid annuloplasty (PASTA) to create a double-orifice valve. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2018;92(3):E175–84. https://doi.org/10.1002/ccd.27531.

    Article  Google Scholar 

  72. Greenbaum AB, Khan JM, Rogers T, et al. First-in-human transcatheter pledget-assisted suture tricuspid annuloplasty for severe tricuspid insufficiency. Catheter Cardiovasc Interv Off J Soc Card Angiogr Interv. 2021;97(1):E130–4. https://doi.org/10.1002/ccd.28955.

    Article  Google Scholar 

  73. Cabasa AS, Eleid MF, Rihal CS, Villarraga HR, Foley TA, Suri RM. Tricuspid valve replacement. JACC Cardiovasc Interv. 2015;8(8):1126–8. https://doi.org/10.1016/j.jcin.2015.03.025.

    Article  PubMed  Google Scholar 

  74. Webb J, Hensey M, Fam N, et al. Transcatheter mitral valve replacement with the transseptal EVOQUE System. JACC Cardiovasc Interv. 2020;13(20):2418–26. https://doi.org/10.1016/j.jcin.2020.06.040.

    Article  PubMed  Google Scholar 

  75. Fam NP, von Bardeleben RS, Hensey M, et al. Transfemoral transcatheter tricuspid valve replacement with the EVOQUE System: a multicenter, observational, first-in-human experience. JACC Cardiovasc Interv. 2021;14(5):501–11. https://doi.org/10.1016/j.jcin.2020.11.045 This observational first-in-human experience demonstrated high technical success, acceptable safety, and significant clinical improvement with the EVOQUE tricuspid valve replacement system.

  76. Edwards Lifesciences. Edwards transcatheter tricuspid valve replacement: investigation of safety and clinical efficacy using a novel device. clinicaltrials.gov; 2021. Accessed Mar 24, 2021. https://clinicaltrials.gov/ct2/show/NCT04221490

  77. Edwards Lifesciences. Edwards EVOQUE transcatheter tricuspid valve replacement: pivotal clinical investigation of safety and clinical efficacy using a novel device. clinicaltrials.gov; 2021. Accessed Mar 24, 2021. https://clinicaltrials.gov/ct2/show/NCT04482062

  78. Navia JL, Kapadia S, Elgharably H, et al. First-in-human implantations of the NaviGate bioprosthesis in a severely dilated tricuspid annulus and in a failed tricuspid annuloplasty ring. Circ Cardiovasc Interv. 2017;10(12). doi:https://doi.org/10.1161/CIRCINTERVENTIONS.117.005840

  79. Hahn RT. Kodali Susheel, Fam Neil, et al. Early multinational experience of transcatheter tricuspid valve replacement for treating severe tricuspid regurgitation. JACC Cardiovasc Interv. 2020;13(21):2482–93. https://doi.org/10.1016/j.jcin.2020.07.008.

    Article  PubMed  Google Scholar 

  80. Lu F-L, Ma Y, Zhao A, et al. First-in-man experience of transcatheter tricuspid valve replacement with LuX-Valve in high-risk tricuspid regurgitation patients. JACC Cardiovasc Interv. 2020;13(13):1614–6. https://doi.org/10.1016/j.jcin.2020.03.026.

    Article  PubMed  Google Scholar 

  81. Xu Z. THE TRAVEL TRIAL: Transcatheter right atrial-ventricular valve replacement with LuX-Valve. clinicaltrials.gov; 2020. Accessed Mar 23, 2021. https://clinicaltrials.gov/ct2/show/NCT04436653

  82. SHDS 2018: TRISOL tricuspid valve replacement: a comprehensive solution for tricuspid regurgitation and RV dysfunction. tctmd.com. Accessed Mar 25, 2021. https://www.tctmd.com/videos/shds-2018-trisol-tricuspid-valve-replacement-a-comprehensive-solution-for-tricuspid-regurgitation-and-rv-dysfunction.5802189567001

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, New York Medical College at Westchester Medical Center, Valhalla, NY, USA

    Srikanth Yandrapalli MD

  2. Cardiology Division, Massachusetts General Hospital and Harvard Medical School, 55 Fruit Street, Yawkey 5B, Boston, MA, 02114, USA

    Dhaval Kolte MD, PhD

Authors
  1. Srikanth Yandrapalli MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dhaval Kolte MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dhaval Kolte MD, PhD.

Ethics declarations

Conflict of Interest

Srikanth Yandrapalli and Dhaval Kolte declare no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Valvular Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yandrapalli, S., Kolte, D. Tricuspid Regurgitation: When and How to Treat. Curr Treat Options Cardio Med 23, 60 (2021). https://doi.org/10.1007/s11936-021-00938-x

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s11936-021-00938-x

Keywords

Search

Navigation